Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Sponsor: Concert Pharmaceuticals
Listed as NCT03137381, this PHASE2 trial focuses on Alopecia Areata and remains completed. Sponsored by Concert Pharmaceuticals, it has been updated 16 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 11 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2019 — Aug 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Feb 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Jun 2017 — Aug 2017 [monthly]
Suspended PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Concert Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .